Introduction: The prevalence of celiac disease (CeD) in first and second degree family members is estimated to be 7.5% and 2.3%, respectively (Singh P., et al. 2015). Family members are often unaware of their increased risk of CeD and best practices for identifying CeD in at-risk individuals are unknown. Methods: We conducted a community-wide screening event of first and second degree family members of patients diagnosed with CeD. Family members were recruited through patient and provider letters, patient telephone contacts, social media posts, email notices, television media, websites and physician encounters in the clinic setting. Eligibility was restricted to family members who were: ≥ 18 years of age, on a gluten-containing diet, not previously diagnosed with CeD, and not known to have an absence of the HLA-DQ2 or DQ8 haplotypes. Participants completed a questionnaire to assess eligibility, symptoms, comorbidities, health-related quality of life and family history. The event was held on a single day in a community-based, outpatient clinic location. Serology assessments included tTG-IgA, IgA and IgG Deamidated Gliadin Peptide (DGP). Serology results were characterized as positive (>10 U/mL for tTG-IgA antibodies), equivocal (tTG-IgA ≥7 and ≤10 U/mL or DGP ≥7 in the absence of elevated tTG), or negative (Phadia 250, Thermo Fisher Scientific, USA). Results: A total of 147 family members registered on-line for the event. Of these, 114 were confirmed as eligible and participated in the event. Overall, 5.2% of participants (n=6) had an abnormal serologic test. From these, two (1.8%; 95% CI 0.3%, 5.7%) participants were positive, and four (3.5%; 95% CI: 1.1%, 8.2%) participants tested equivocal. Of the four with an equivocal test result, all had a tTG-IgA result of < 2 U/mL. Of the tested cohort, 16 (14.9%) had previously tested negative for CeD, and of these, one patient tested equivocal (Table 1). Clinical and demographic characteristics between participants with abnormal vs. seronegative results were similar (Tables 1-2).Table: *TTG IGA >10 U/mL = positive (n=2); TTG IGA ≥7 and ≤10 U/mL, Deamidated Gliadin G ≥7, or Deamidated Gliadin A ≥7 = equivocal (n=4).Table: *TTG IGA >10 U/mL = positive (n=2); TTG IGA ≥7 and ≤10 U/mL, Deamidated Gliadin G ≥7, or Deaminated Gliadin A ≥7 = equivocal (n=4).Conclusion: On this one day event, 1.8% of participants (n=2) were identified to have a positive serologic test and 5.2% of participants (n=6) were identified as having an abnormal serologic test and may warrant further clinical evaluation. Family screening events may increase CeD diagnosis, however additional research is needed to determine which family members may be at increased risk.